University Staff

Prof. H.Y.S. Ngan hong kong university logo queen mary hosipital logo

Prof Hextan Yuen-Sheung NGAN (顏婉嫦教授)

Tsao Yin-Kai Professor in Obstetrics and Gynaecology,
  • Chair Professor,
  • Head of Department
    MBBS(HK), MD(HK), FRCOG(UK), FHKCOG(HK), FHKAM (O&G); Cert RCOG (Gynae Onc); Accredited gynaecological oncologist (UK and HK); Accredited colposcopist (HKCOG/HKSCCP, HK)
    • location
      6/F, Professorial Block, Queen Mary Hospital
    • telephone
      (852)-2255-4260
    • facsimile
      (852)-2855-0947
    • lsmlai@hku.hk
    • HKU Scholars Hub
    Research Interests

         My research interests include basic, clinical and translational cancer research in gynaecology oncology. My basic research interests have focus on the characterization of putative oncogenes and tumor suppressor genes, as well as their associated signaling pathways involved in the pathogenesis of ovarian, endometrial and cervical carcinomas. Our research team was the first to identify p73alpha is involved in enhancement of the radiosensitive in cervical cancer cells through with the upregulation of p21. Importantly, our team has recently found that the breast cancer–associated gene 3 (BCA3) acts as a novel protein interacting partner of TAp73 and potentiates TAp73 in mediating γ-irradiation–induced apoptosis. These studies reveal the significance of p73 in the radiosensitivity of cervical cancer cells. Moreover, my group has recently reported an important oncogenic transcriptional factor, FOXM1, is frequently overexpressed in cervical and ovarian cancers, and is significantly correlated with the progression and aggressiveness of these cancers. The inhibitory targeting of FOXM1 by RNAi, specific inhibitor e.g. thiostrepton, or even AMPK activators such as metformin could remarkably abrogate the oncogenic capacities of these cancer cells. Ovarian cancer is a relatively poor survival rate disease because of chemoresistance and high rate in tumor recurrence. Hence, our team is particularly interested in the delineation of the underlying mechanisms associated with tumorigenesis and chemoresistance of this disease. Recent studies in our team has not only identified the oncogenic role of FOXM1 in ovarian cancer, they also have found the signaling adaptors, GRB7 and its variant GRB7v, are aberrantly upregulated and associated with a variety of oncogenic capacities by modulating differential signaling pathways. These findings may shed the light of exploring potential therapeutic interventions through targeting these genes. Future studies will include the study of the impacts of tumor microenvironment and cancer cell metabolism on these key pathways involved in the aggressiveness and chemoresistance of ovarian cancer.
         My clinical translational research effort have focused on cervical cancer screening especially on the role of HPV testing as well as on psychosocial studies including quality of life. In addition, the identification of new molecular markers in addition to routine HPV screening test is another area of my interested research. Currently my group is conducting a study to compare different HPV test. Lastly, our team has also taken part in contract clinical trials mainly in ovarian cancer treatment and HPV vaccines.

    • Gynaecological oncology – basic and clinical research including HPV, oncogenes, tumour suppressor genes, epigenetic studies and drug trials
    • Cervical cancer screening – basic and clinical research including HPV, cytology, colposcopy studies
    • Psychosocial studies – quality of life, psychosocial and psychosexual studies
    PubMed Search

    Author Name: Ngan HY

    Publications

    2017
    • Ngu SF, Wei N, Kwan TT, Chu MM, Tse KY, Chan KK, Ngan HY. Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: a randomised trial. J Psychosom Obstet Gynaecol. 2017 Apr 10:1-10.

    • Ngu SF, Chu MM, Ip PP, Ngan HY. Vulvar Hidradenitis Suppurativa: Is the Mass Malignant? J Obstet Gynaecol Can. 2017 Mar 30. S1701-2163(16)39741-9.

    2016
    • Chu MM, Tse KY, Chan KK, Cheung AN, Ngan HY. Placental Site Trophoblastic Tumour – A Distinct Entity of Gestational Trophoblastic Disease. Experience from a tertiary referral center in Hong Kong. J Reprod Med. 2016 Aug;61(4):351-6

    2015
    • Tse KY and Ngan HYS. The role of laparoscopy in staging of different gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2015, S1521-6934 (15)00030-9.

    • Siu KY, Kong DS, Ngai SY, Chan HY, Jiang L, Wong ESY, Liu S, Chan KKL, Ngan HYS and Cheung ANY. p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation. PLoS One 2015, 10(7): e0133467.

    • Park JY, Ngan HY, Park W, Cao Z, Wu X, Ju W, Chung HH, Chang SJ, Park SY, Ryu SY, Kim JH, Cho CH, Lee KH, Lee JW, Kumarasamy S, Kim JW, Wilailak S, Kim BG, Kim DY, Konishi I, Lee JK, Wang KL, Nam JH. Asian Society of Gynecologic Oncology International Workshop 2014. J Gynecol Oncol 2015 Jan;26(1):68-74.

    • Ngu SF and Ngan HYS. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015, http://dx.doi.org/10.1016/j.bpobgyn.2015.10.007

    • Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2015 Oct;131 Suppl 2:S123-6.

    • Mak VC, Wong OG, Siu MK, Wong ES, Ng WY, Wong RW, Chan KK, Ngan HY, Cheung AN. FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling. Am J Pathol 2015 Jul;185(7):2038-48.

    • Leung TW, Liu S, Leung CY, Chu MM, Cheung ANY and Ngan HYS. HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis. J Med Virol 2015, 2015 Jun;87(6):1022-33.

    • Chu MYM, Liu S, Tam KF, Ip PCP, Cheung ANY and Ngan HYS. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer. Int J Gynecol Pathology 2015, 34: 403-410.

    • Chu MM, Ma Y, Tse KY, Chan KK, Ngan HY. Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. International Journal of Gynecological Cancer 2015 Mar;25(3):498-503.

    2014
    • Lee EY, Yu X, Chu MM, Ngan HY, Siu SW, Soong IS, Chan Q, Khong PL. Perfusion and diffusion characteristics of cervical cancer based on intraxovel incoherent motion MR imaging-a pilot study. Eur Radiol. 2014 Jul;24(7):1506-13

    • Liu X, Siu KY, Liu S, Yam JWP, Ngan HYS and Chan DW. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5: 944–958.

    • Li C, Liu VWS, Chiu PM, Yao KM, Ngan HYS and Chan DW. Reduced expression of AMPK-beta1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Molecular Cancer 2014, 13: 49.

    • Leung CO, Deng W, Ye TM, Ngan HYS, Tsao SW, Cheung ANY, Pang RTK and Yeung WSB. miR-135a leads to cervical cancer cell transformation through regulation of β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. Carcinogenesis 2014 Sep;35(9):1931-40.

    • Chan KKL, Leung THY, Chan DW, Wei N, Lau TY, Liu S, Siu KY and Ngan HYS. Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer. Journal of Endocrinology 2014, 221: 325-336.

    • Cai C, Shi L, Liu VWS, Tang WM, Liu J, Leung THY, Chan KKL, Yam JWP, Yao KM, Ngan HYS and Chan DW. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget 2014, 5: 7549-62.

    2013
    • Lee EY, Khong PL, Tse KY, Chan KK, Chu MM, Ngan HY. Differentiation of aggressive and indolent subtypes of uterine sarcoma using maximum standardized uptake value. Nucl Med Commun. 2013; 34(12):1185-9.

    • Kwan HT, Chan DW, Cai PC, Mak CS, Yung MM, Leung TH, Wong OG, Cheung AN, Ngan HY. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PLoS One. 2013;8(1):e53597. [PubMed]

    • Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY.The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer. 2013 Aug 20;109(4):965-75. [PubMed]

    • Chan RW, Mak AS, Yeung WS, Lee KF, Cheung AN, Ngan HY, Wong AS. Human female reproductive tract epithelial cell culture. Methods Mol Biol. 2013;945:347-63. [PubMed]

    • Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN. Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis. 2013 Jun 17. [Epub ahead of print] [PubMed]

    • Obermair A, Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, Carter J, Leung Y, Janda M. Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer. 2013 Feb;23(2):264-7. [PubMed]

    • Siu MK, Wong ES, Kong DS, Chan HY, Jiang LL, Wong OS, Lam EW, Chan KK, Ngan HY, Le XF, Cheung AN. Stem cell transcription factor Nanog promotes ovarian cancer cell migration and invasion through E-cadherin and FOXJ1 and associates with poor prognosis in patients. Oncogene 2013; 32:3500-9. [PubMed]

    • Yung MM, Chan DW, Liu VW, Yao KM, Ngan HY. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 2013 Jul 3;13:327. doi: 10.1186/1471-2407-13-327. [PubMed]

    2012
    • Chan DW, Hui WY, Cai C, Liu X, Yung MH, Mak SL, Leung THY, Chan KKL, Ngan HYS. Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells. PLoS ONE. 2012, 7: e52578. [PubMed]

    • Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget. 2012 Dec;3(12):1546-56. [PubMed]

    • Chan DW, Ngan HYS. The potential molecular therapeutic approach in targeting ovarian clear cell carcinoma, Gynecology & Obstetrics. OMICS Group, 2012, 2: 1000e103. 

    • Chan KKL, Kwan TTC, Yao T, Tam KF, Cheung ANY, Ngan HYS. Human papillomavirus vaccine: What are women most concerned about? J Obstet Gynaecol Res. 2012, 38(1): 23-30. 

    • Fung FK, Chan DW, Liu VW, Leung TH, Cheung AN, Ngan HY. Increased expression of PITX2 transcription factor contributes to ovarian cancer progression. PLoS One. 2012;7(5):e37076. [PubMed]

    • Garland SM, Bhatla N, Ngan HY. Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1414-22. 

    • Kondalsamy-Chennakesavan S, Janda M, Gebski V, Baker J, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede DH, Pather S, Simcock B, Farrell R, Robertson G, Walker G, McCartney A, Obermair A. Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012 Sep;48(14):2155-62.

    • Kwan TT, Lo SS, Tam KF, Chan KK, Ngan HY. Assessment of knowledge and stigmatizing attitudes related to human papillomavirus among Hong Kong Chinese healthcare providers. Int J Gynaecol Obstet. 2012 Jan;116(1):52-6. 

    • Li C, Liu VW, Chan DW, Yao KM, Ngan HY. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer. 2012 Jan;22(1):15-22. [PubMed]

    • Li C, Liu VW, Chiu PM, Chan DW, Ngan HY. Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer. 2012 Aug 16;12:357. [PubMed]

    • Liu X, Chan DW, Ngan HYS. Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance. Gynecology & Obstetrics. 2012; 2:1000e104. [PubMed]

    • Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY, Cheung AN. Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol 2012; 27:1121-30. [PubMed]

    • Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, Seckl MJ, Sasaki S, Soper JT. Trophoblastic disease. Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S130-6. 

    • Obermair A, Janda M, Baker J, Kondalsamy-Chennakesavan S, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede DH, Pather S, Simcock B, Farrell R, Robertson G, Walker G, McCartney A, Gebski V. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012 May;48(8):1147-53.

    • Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le XF, Cheung AN. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201. [PubMed]

    • Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, Carter J, Leung Y, Obermair A. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). Gynecol Oncol. 2012 Jul;126(1):36-40. [PubMed]

    • Tse KY, Ngan HY. Gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):357-70. [PubMed]

    • Wei N, Liu SS, Chan KK, Ngan HY. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One. 2012;7(1):e30311. [PubMed]

    • Wong OG, Lo CK, Chow JN, Tsun OK, Szeto E, Liu SS, Ngan HY, Cheung AN. Comparison of the GenoFlow human papillomavirus (HPV) test and the Linear Array assay for HPV screening in an Asian population. J Clin Microbiol. 2012 May;50(5):1691-7. [PubMed]

    • Zhang P, Liu SS, Ngan HY. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One. 2012;7(8):e42985. [PubMed]

    2011
    • Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, Lau SK, Yip MW, Ngan HY. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol. 2011 Oct;22(10):2241-9. [PubMed]

    • Chan DW, Liu VW, Leung LY, Yao KM, Chan KK, Cheung AN, Ngan HY. Zic2 synergistically enhances Hedgehog signalling through nuclear retention of Gli1 in cervical cancer cells. J Pathol. 2011 Dec;225(4):525-34. [PubMed]

    • Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC, Wong AS. P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin. Oncogene. 2011 Jun 30;30(26):2964-74.

    • Ip CK, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011 May 26;30(21):2420-32. 

    • Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, Chan HY, Cheung AN. iASPP and Chemoresistance in Ovarian Cancers – Effects on Paclitaxel-Mediated Mitotic Catastrophe. Clin Cancer Res 2011; 17:6924-6933. [PubMed]

    • Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, Ngan HY. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet Gynecol Scand. 2011 May;90(5):445-51. 

    • Kwan TT, Tam KF, Lee PW, Chan KK, Ngan HY. The effect of school-based cervical cancer education on perceptions towards human papillomavirus vaccination among Hong Kong Chinese adolescent girls. Patient Educ Couns. 2011 Jul;84(1):118-22.

    • Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, Ngan HY. Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011 May 3;6(5):e19244.

    • Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One. 2011;6(8):e23790. [PubMed]

    • Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN. Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Mod Pathol. 2011 Apr;24(4):522-32.

    • Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN. Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Mod Pathol. 2011 Apr;24(4):522-32.

    • Ngan HY, Garland SM, Bhatla N, Pagliusi SR, Chan KK, Cheung AN, Chu TY, Domingo EJ, Qiao YL, Park JS, Tay EH, Supakarapongkul W. Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol. 2011;2011:794861. 

    • Ngan HY. Preface. Uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):679. 

    • Tam KF, Cheung AN, Szeto E, Ngan HY. Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):213-6.

    • Tse KY, Crawford R, Ngan HY. Staging of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):733-49. 

    • Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, Wong OG, Zhang H, Cheung AN. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis 2011; 32:765-71. [PubMed]

    • Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, Wong OG, Zhang HQ, Cheung AN. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis. 2011 May;32(5):765-71. 

    • Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Chan HY, Cheung AN. Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival. Histopathology. 2011 Dec;59(6):1163-72. [PubMed]

    • Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Chan HY, Cheung AN. Overexpression of Dock180 in ovarian cancer correlated with aggressive phenotype and poor patients’ survival. Histopathology 2011; 59: 1163-72. [PubMed]

    2010
    • Cheung ANY, Tsun OKL, Ng KM, Szeto EF, Siu KY, Wong ESY, Ngan HYS. P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytology—potential biomarkers for diagnosis and progress prediction of cervical neoplasia. Modern Pathology 2010;23:559-66. (Publication No. : 176804) 

    • Chow SN, Soon R, Park JS, Pancharoen C, Qiao YL, Basu P, Ngan HYS. Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccinatin amongst urban Asian mothers and physicians. Vaccine 2010;28:3809-17. (Publication No. : 171555) 

    • Hu YJ, Ip PP, Chan KK, Tam KF, Ngan HY. Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor. Int J Gynecol Pathol 2010;29:539-45.

    • Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, McCartney A, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Walsh T, Sykes P, Ngan HYS, Garrett A, Laney M, Ng TY, Tam KF, Chan KKL, Wrede CDH, Pather S, Simcock B, Farrell R, Obermair A. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomized trial. Lancet Oncol. 2010;11:772-80. (Publication No. : 175333) 

    • Jiang L, Siu MK, Wong OG, Tam KF, Lam EW, Ngan HY, Le XF, Wong ES, Chan HY, Cheung AN. Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol Cancer. 2010;9:318.

    • Kwan TT, Tam KF, Lee PW, Lo SS, Chan KK, Ngan HY. De-stigmatising human papillomavirus in the context of cervical cancer: a randomised controlled trial. Psychooncology 2010;19:1329-39.

    • Leung TH, Ngan HY. Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiation-induced apoptosis. Cancer Res 2010;70:6486-96. [PubMed]

    • Liu S, Leung CY, Chan KKL, Cheung ANY, Ngan HYS. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay by comparison with Roche Linear Array HPV genotyping assay. Journal of Clinical Microbiology. 2010;48:758-64. (Publication No. : 176805) 

    • Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-14.

    • Ngan HYS, Cheung ANY, Tam KF, Chan KKL, Tang HW, Bi D, Descamps D, Bock HL. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong, Hong Kong Med J 2010;16:171-9. (Publication No. : 170837) 

    • Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Strömblad S, Cheung AN. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A. 2010;107:18622-7.

    • Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK, ChanDC, ChanKY, Cheung AN. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int J Cancer. 2010 Jul 1;127(1):21-31.

    • SiuKY, Yeung CW, Zhang H, Kong SH, Ho WKJ, Ngan HYS, ChanDC, Cheung ANY. p21-activated kinase 1 promotes aggressive phenotype, cell proliferation and invasion in gestational trophoblastic disease. Am J Pathol 2010;176:3015-22. (Publication No. : 176674)

    • Suh DH, Kim JW, Aziz MF, Devi UK, Ngan HY, Nam JH, Kim SC, Kato T, Ryu HS, Fujii S, Lee YS, Kim JH, Kim TJ, Kim YT, Wang KL, Lee TS, Ushijima K, Shin SG, Chia YN, Wilailak S, Park SY, Katabuchi H, Kamura T, Kang SB. Asian society of gynecologic oncology workshop 2010. J Gynecol Oncol. 2010;21:137-50.

    • Wang Y, Chan DW, Liu VWS, Chiu PM, Ngan HYS. Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis, Clinical Cancer Research 2010;16:2529-39. [PubMed]

    • Zhang HJ, Siu MK, Jiang LL, Mak VC, Ngan HY, Cheung AN. Overexpression of the Parkinson disease protein DJ-1 and its regulator PTEN in gestational trophoblastic disease. Int J Gynecol Pathol. 2010;29:468-75.

    2008
    • Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW, Cheung AN, Ngan HY. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol. 2008 Jul;215(3):245-52. [PubMed]

    • Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol. 2008 Jan;111(1):144-51. [PubMed]

    • Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, Ngan HY. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 2008 Sep;29(9):1742-50.  [PubMed]

    Research Grants
    • Roles of HPV-E6 protein and CD55(+) population in regulating radio-resistance in cervical cancer cells. University Grant Committee of Hong Kong (UGC) Research Grant Council (RGC) General Research Fund (GRF) 2013-2014 (Principal Investigator) HK$ 1,255,747 (2013-2016)
    • Functional characterization and clinical significance of DNp73-C35 in ovarian cancer. University Grant Committee of Hong Kong (UGC) Research Grant Council (RGC) General Research Fund (GRF) 2011-2012 (Principal Investigator) HK$ 1,092,500 (2011-2014)